Jim Omel
@IMFjimMYELOMA
Followers
3K
Following
6K
Media
464
Statuses
7K
Myeloma since 1997. Retired from Family Practice after SCT. Cancer research advocate with NCI, Alliance, CIBMTR, FDA, many other areas.
Joined November 2014
Dr Raza on Talquetamab Plus Teclistamab in R/R Myeloma and Extramedullary Disease via @onclive Very effective ORR, with a SE of low immune protection.
onclive.com
Shahzad Raza, MD, discusses talquetamab in plus teclistamab in relapsed/refractory multiple myeloma with extramedullary disease.
0
0
0
Creating Space for Ide-Cel and Finding Sequencing Options in Multiple Myeloma via @@CancerNetwrk.
cancernetwork.com
Experts debate cutting-edge multiple myeloma treatments, exploring pressing data, the most prominent news, and patient cases.
0
0
1
Thanks @mtmdphd i’m doing well Mike, and it’s been far too long since we’ve seen each other.
@IMFjimMYELOMA @cure_today @MyelomaTeacher @NorthTxMSG @VincentRK @IMFsupport Thanks for sharing Jim. I hope you are well.
0
0
4
Why New Patients With Multiple Myeloma ‘Can Expect Long, Healthy Lives’ via @cure_today For most patients myeloma has become a chronic disease. @MyelomaTeacher @NorthTxMSG @VincentRK @IMFsupport.
curetoday.com
Dr. Jim Omel, who was diagnosed with multiple myeloma in 1997, explained how the treatment landscape has changed over nearly 30 years.
1
8
23
Designated Pharmacist Can Reduce Risk of ADRs in Patients With Hematologic Malignancies Have a pharmacist on your treatment team.
cancertherapyadvisor.com
This study “provides compelling evidence for incorporating oncology-trained pharmacists into hematology-oncology care teams,” researchers wrote.
0
0
1
Many Ineligible for Clinical Trial Could Benefit From Teclistamab for Multiple Myeloma There’s no waiting. It’s off the shelf ready to administer. And effective.
hematologyadvisor.com
89 percent of 509 patients would have been ineligible for MajesTEC-1 trial; estimated median PFS was 5.8 months.
1
3
12
3-Year MRD Negativity Drives Lenalidomide Discontinuation in Myeloma Safely getting off of #myeloma trtmt.
hematologyadvisor.com
Discontinuing lenalidomide maintenance after 3 years of MRD negativity following multiple myeloma treatment was associated with high PFS and TFS rates.
0
3
4
Experts Say Rural Emergency Rooms Are Increasingly Run Without Doctors This is quite common in rural America.
medpagetoday.com
PAs and NPs fill in the gaps amid nationwide doctor shortage
0
0
0
RT @NebraskaMed: It happened again! For the 14th straight year, Nebraska Medical Center has been named the best hospital in Nebraska by U.S….
0
4
0
Many Ineligible for Clinical Trial Could Benefit From Teclistamab for Multiple Myeloma #mmsm.
oncologynurseadvisor.com
89 percent of 509 patients would have been ineligible for MajesTEC-1 trial; estimated median PFS was 5.8 months.
1
1
6
Karen's Story: Navigating Multiple Myeloma Treatment Lines via @@CancerNetwrk.
cancernetwork.com
Panelists discuss how multiple myeloma patients navigate complex treatment journeys through multiple relapses, clinical trials, and the transformative potential of bispecific antibody therapies like...
0
0
2
A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma - ResearchGate - #GoogleAlerts mezigdomide trial. Is this Celmod getting close to approval?.
researchgate.net
Request PDF | A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma | Cancer vaccines are emerging as promising therapies to not only prevent cancer but to treat cancer. Here, we...
1
0
7
Belantamab Mafodotin Combos Receive EU Approval for R/R Multiple Myeloma via @@CancerNetwrk Bela is approved in Europe. It’s approved in Canada. Why can’t we have it in USA, FDA?.
cancernetwork.com
Phase 3 DREAMM-7 and DREAMM-8 trial results showed that combinations with belantamab mafodotin showed superior efficacy vs standard of care in the disease.
0
3
8
Isolated relapse of multiple myeloma in the central nervous system post autologous . - PubMed - #GoogleAlerts This is rare!.
pubmed.ncbi.nlm.nih.gov
This case report retrospectively evaluated the diagnosis and treatment of a multiple myeloma (MM) patient with early relapse in the central nervous system (CNS) post autologous hematopoietic stem...
0
1
4
What to Know About Treating Frail Elderly Patients With Multiple Myeloma
medpagetoday.com
Challenging, especially because of the difference between promising trials and real-world patients
0
0
2
For Your Patients: Getting to Know the Options for Newly Diagnosed Multiple Myeloma
medpagetoday.com
New drug regimens, with or without transplant, are improving quality of life, prolonging survival
0
0
1
New PDUFA date is October 23.
FDA extends review period for GSK’s Blenrep in multiple myeloma #mmsm
0
0
2
This myeloma patient and research advocate hopes so too, @MyelomaTeacher Other countries are certainly approving Blenrep.
0
2
11
Cancer DNA Can Be Detected in the Bloodstream Up to Three Years Before Diagnosis, Study Suggests - @smithsonianmag Sure beats bone marrow exams!.
smithsonianmag.com
For a few individuals, scientists found genetic material from cancerous tumors in blood samples taken years before they were diagnosed through traditional methods
1
0
1